I-SPY 2 to GBM AGILE and Beyond

In this episode of "In the Interim...," we sit down with Dr. Meredith Buxton to explore the evolution of platform trials from I-SPY 2 to GBM AGILE and Beyond. With a rich history in innovative trial design, Meredith shares the journey from pioneering adaptive clinical trials in breast cancer with I-SPY 2 to her current role at the Global Coalition for Adaptive Research (GCAR). This conversation offers insights into accelerating clinical trial timelines, innovative operational frameworks, and their applications across multiple medical domains, making it a must-listen for anyone involved in clinical development and platform trials.Key Highlights:• Meredith Buxton discusses the origins and groundbreaking operations of the I-SPY platform in breast cancer.• Exploration of how the I-SPY 2 model inspired subsequent platform trials in diverse areas such as glioblastoma and COVID-19.• GCAR's role as a non-profit entity to foster adaptive trial designs and Meredith’s influential contributions to its formation and success.• Discover the operational complexities and regulatory considerations essential for modern platform trials.• Insights into Meredith’s vision for the future of drug development and the ongoing necessity for innovation in trial design.Quotes:• “The ideas of this are groundbreaking in many ways.” – Scott Berry• "The I-SPY2 model could be replicated in other spaces." – Meredith Buxton